Effects of mifepristone on uterine leiomyoma in premenopausal women: A meta-analysis

Fertility and Sterility

Volumn 100, Issue 6, 2013, Pages

  Shen, Qi ^a   Hua, Ying ^a   Jiang, Wenxiao ^a   Zhang, Wenwen ^a   Chen, Miaomiao ^a   Zhu, Xueqiong ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

leiomyoma; meta analysis; Mifepristone

Indexed keywords

AMINOTRANSFERASE; HEMOGLOBIN; MIFEPRISTONE; PLACEBO; ANTINEOPLASTIC AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANEMIA; ARTICLE; BLEEDING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DYSMENORRHEA; ENDOMETRIAL THICKNESS; ENDOMETRIUM HYPERPLASIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUATION; META ANALYSIS; PELVIC PAIN; PELVIC PRESSURE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TUMOR VOLUME; UTERUS MYOMA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE BASED MEDICINE; INCIDENCE; LEIOMYOMA; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; UTERINE NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; LEIOMYOMA; MIFEPRISTONE; PREMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 84888431964     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2013.08.039     Document Type: Article

References (22)

1. S. Okolo Incidence, aetiology and epidemiology of uterine fibroids Best Pract Res Clin Obstet Gynaecol 22 2008 571 588
2. M.S. Islam, O. Protic, S.R. Giannubilo, P. Toti, A.L. Tranquilli, and F. Petraglia Uterine leiomyoma: available medical treatments and new possible therapeutic options J Clin Endocrinol Metab 98 2013 921 934
3. H. Ishikawa, K. Ishi, V.A. Serna, R. Kakazu, S.E. Bulun, and T. Kurita Progesterone is essential for maintenance and growth of uterine leiomyoma Endocrinology 151 2010 2433 2442
4. S.H. Eisinger, J. Fiscella, T. Bonfiglio, S. Meldrum, and K. Fiscella Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata Eur J Obstet Gynecol Reprod Biol 146 2009 215 218
5. S. Mukherjee, and S. Chakraborty A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri Niger Med J 52 2011 150 152
6. S.H. Eisinger, T. Bonfiglio, K. Fiscella, S. Meldrum, and D.S. Guzick Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas J Minim Invasive Gynecol 12 2005 227 233
7. M. Engman, S. Granberg, A.R. Williams, C.X. Meng, P.G. Lalitkumar, and K. Gemzell-Danielsson Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial Hum Reprod 24 2009 1870 1879
8. M. Oremus, C. Wolfson, A. Perrault, L. Demers, F. Momoli, and Y. Moride Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials Dement Geriatr Cogn Disord 12 2001 232 236
9. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
10. M. Bagaria, A. Suneja, N.B. Vaid, K. Guleria, and K. Mishra Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial Aust N Z J Obstet Gynaecol 49 2009 77 83
11. J.L. Carbonell Esteve, R. Acosta, B. Heredia, Y. Pérez, M.C. Castañeda, and A.V. Hernández Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial Obstet Gynecol 112 2008 1029 1036
12. J.L. Carbonell Esteve, R. Acosta, Y. Pérez, R. Campos, A.V. Hernández, and C.S. Texidó Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial Eur J Obstet Gynecol Reprod Biol 161 2012 202 208
13. J.L. Carbonell Esteve, A.M. Riverón, M. Cano, A.I. Ortiz, A. Valle, and C.S. Texidó Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery Int J Womens Health 4 2012 75 84
14. S.H. Eisinger, S. Meldrum, K. Fiscella, H.D. le Roux, and D.S. Guzick Low-dose mifepristone for uterine leiomyomata Obstet Gynecol 101 2003 243 250
15. C. Feng, S. Meldrum, and K. Fiscella Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone Int J Gynaecol Obstet 109 2010 121 124
16. K. Fiscella, S.H. Eisinger, S. Meldrum, C. Feng, S.G. Fisher, and D.S. Guzick Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size a randomized controlled trial Obstet Gynecol 108 2006 1381 1387
17. J. Fiscella, T. Bonfiglio, P. Winters, S.H. Eisinger, and K. Fiscella Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone Hum Pathol 42 2011 947 953
18. L. Yu, A.B. Moore, and D. Dixon Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma Semin Reprod Med 28 2010 250 259
19. J.J. Kim, and E.C. Sefton The role of progesterone signaling in the pathogenesis of uterine leiomyoma Mol Cell Endocrinol 358 2012 223 231
20. M. Koskas, N. Chabbert-Buffet, S. Douvier, C. Huchon, E. Paganelli, and J. Derrien Role of medical treatment for symptomatic leiomyoma management in premenopausal women J Gynecol Obstet Biol Reprod (Paris) 40 2011 858 874
21. A.A. Murphy, L.M. Kettel, A.J. Morales, V.J. Roberts, and S.S. Yen Regression of uterine leiomyomata in response to the antiprogesterone RU 486 J Clin Endocrinol Metab 76 1993 513 517
22. R.C. Reinsch, A.A. Murphy, A.J. Morales, and S.S. Yen The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study Am J Obstet Gynecol 170 1994 1623 1627